viral
respiratori
infect
common
caus
acut
asthma
exacerb
children
adult
repres
signific
global
health
burden
increas
bodi
evid
support
hypothesi
infect
caus
greater
degre
morbid
asthmat
subject
healthi
popul
emphas
discrep
antivir
respons
asthmat
review
discuss
discrep
might
exist
examin
role
bronchial
epithelium
well
main
inflammatori
cell
mediat
molecular
pathway
involv
immun
respons
addit
potenti
impact
virusinduc
asthma
exacerb
airway
remodel
review
explor
therapeut
option
might
benefit
prevent
deterior
asthma
control
seen
follow
viral
infect
j
allergi
clin
immunol
key
word
asthma
acut
exacerb
viru
viral
respiratori
tract
infect
one
common
ill
human
subject
million
case
econom
burden
estim
billion
annual
unit
state
alon
sinc
earli
viral
respiratori
tract
infect
report
trigger
exacerb
asthma
adult
children
develop
highli
sensit
specif
molecular
diagnost
detect
techniqu
led
greatli
improv
detect
respiratori
tract
virus
allow
clear
demonstr
import
link
viral
infect
asthma
exacerb
rtpcr
use
supplement
instead
convent
cultur
techniqu
virus
found
approxim
wheez
episod
schoolag
children
approxim
one
half
three
quarter
acut
wheez
episod
adult
respiratori
tract
virus
identifi
circumst
rhinovirus
commonli
found
detect
approxim
time
addit
rhinovirus
respiratori
tract
virus
respiratori
syncyti
viru
rsv
influenza
virus
coronavirus
human
metapneumovirus
parainfluenza
virus
adenovirus
bocavirus
detect
subject
asthma
exacerb
howev
recent
epidemiolog
studi
perform
discoveri
sever
newer
virus
bocaviru
viru
type
significantli
associ
asthma
exacerb
children
age
year
rhinovirus
understand
mechan
provok
virusinduc
airway
inflamm
asthmat
subject
might
offer
signific
opportun
improv
diseas
manag
realiti
present
current
drug
treatment
virusinduc
exacerb
asthma
poorli
effect
altern
therapi
modul
viral
pathogenesi
desper
need
experiment
human
murin
model
rhinovirusinduc
asthma
exacerb
recent
develop
offer
great
potenti
increas
understand
goal
arriv
novel
therapi
futur
recent
studi
kind
experiment
infect
asthmat
healthi
volunt
rhinoviru
led
increas
lower
respiratori
tract
symptom
typic
mild
exacerb
asthmat
subject
minim
lower
respiratori
tract
symptom
healthi
volunt
increas
airway
hyperrespons
decreas
peak
expiratori
flow
fev
demonstr
asthmat
subject
without
chang
measur
healthi
subject
studi
along
sever
other
support
idea
respiratori
tract
viral
infect
caus
greater
degre
morbid
asthmat
subject
healthi
popul
review
discuss
discrep
antivir
immun
respons
might
exist
addit
explor
therapeut
option
might
benefit
prevent
deterior
asthma
control
seen
viral
infect
bronchial
epithelium
provid
barrier
microberich
outsid
world
intern
parenchyma
howev
far
simpli
inert
barrier
immunolog
activ
play
pivot
role
innat
adapt
immun
respiratori
tract
virus
enter
replic
within
airway
epitheli
cell
damag
ciliat
noncili
respiratori
epitheli
cell
lead
necrosi
airway
epithelium
ciliostasi
loss
cilia
impair
mucociliari
clearanc
howev
like
clinic
manifest
might
secondari
releas
proinflammatori
mediat
damag
bronchial
epitheli
cell
bec
well
direct
cytotox
effect
viru
rhinovirus
attach
epitheli
cell
intercellular
adhes
molecul
major
human
rhinoviru
hrv
serotyp
lowdens
lipoprotein
receptor
minor
hrv
serotyp
receptor
receptor
recent
identifi
group
c
rhinovirus
yet
identifi
inde
rhinoviru
infect
upregul
express
vivo
vitro
avail
receptor
bind
infect
epitheli
cell
infect
bec
rhinoviru
induc
secret
wide
rang
cytokin
chemokin
includ
gmcsf
rant
protein
well
mani
other
becderiv
cytokin
chemokin
abl
induc
neutrophil
lymphocyt
eosinophil
inflamm
well
airway
hyperrespons
airway
remodel
howev
also
initi
antivir
immun
respons
highlight
delic
balanc
exist
harm
protect
influenc
asthmat
airway
corn
et
al
demonstr
sever
prolong
virusinduc
symptom
includ
lower
respiratori
tract
symptom
asthmat
compar
nonasthmat
subject
suggest
first
time
might
inher
differ
way
asthmat
subject
respond
respiratori
tract
viral
infect
wark
et
al
subsequ
provid
mechanist
insight
might
case
studi
involv
cultur
bec
adult
asthmat
nonasthmat
subject
obtain
mean
bronchoscopi
follow
infect
rhinoviru
vitro
although
rhinoviru
induct
proinflammatori
cytokin
differ
group
asthmat
bec
produc
lower
level
type
ifnb
also
higher
level
rhinoviru
replic
importantli
defici
ifnb
express
observ
steroidtr
steroidna
asthmat
subject
asthmat
bec
respond
exogen
treatment
ifnb
exhibit
reduc
rhinoviru
releas
demonstr
defici
asthmat
cell
associ
product
antivir
ifnb
rather
action
ifnb
contoli
et
al
provid
evid
import
antivir
interferon
use
human
experiment
infect
model
adult
mildtomoder
asthma
bronchoalveolar
lavag
bal
cell
asthmat
subject
lower
level
rhinoviru
lpsinduc
type
iii
ifnl
defici
ifnl
asthmat
cell
relat
pathogenesi
asthma
exacerb
vivo
abund
ifnl
neg
correl
airway
symptom
score
chang
lung
function
viru
load
marker
inflamm
vivo
recent
studi
time
subject
moderatetosever
asthma
bullen
et
al
demonstr
mrna
level
obtain
sputum
cell
neg
correl
asthma
symptom
highlight
protect
role
ifnl
asthma
present
precis
mechan
mechan
behind
defici
interferon
product
asthmat
subject
remain
unknown
asthmat
subject
defici
ifnb
ifnl
perhap
ifna
less
like
result
polymorph
one
gene
promot
polymorph
gene
encod
transcript
factor
signal
molecul
requir
express
interferon
like
possibl
howev
interestingli
thoma
et
al
recent
demonstr
excess
tgfb
present
asthmat
airway
mediat
enhanc
rhinoviru
replic
probabl
suppress
action
host
type
interferon
respons
specif
effect
tgfb
appear
mediat
action
interferon
regulatori
factor
irf
pathway
macrophag
predomin
leukocyt
airway
distribut
upper
airway
alveoli
produc
inflammatori
cytokin
recruit
cell
adapt
immun
system
express
number
innat
patternrecognit
receptor
prr
play
key
role
phagocytosi
bacteri
organ
also
modul
immun
respons
inhibit
antigen
present
dendrit
cell
tcell
activ
bcell
antibodi
product
interact
rhinovirus
macrophag
stimul
secret
proinflammatori
cytokin
ifng
inflammatori
protein
addit
tnfa
highli
inflammatori
cytokin
produc
macrophag
respons
rhinoviru
shown
requir
viral
replic
rhinoviru
infect
also
induc
releas
type
interferon
airway
macrophag
process
might
limit
viral
spread
induc
antivir
state
epitheli
cell
recent
oliv
et
al
identifi
virusinduc
impair
antibacteri
host
defens
human
alveolar
macrophag
suggest
viral
infect
might
alter
function
facilit
addit
bacteri
infect
increas
neutrophil
count
level
potent
chemoattract
neutrophil
found
nasal
secret
sputum
bal
fluid
allerg
subject
undergo
experiment
rhinoviru
infect
teran
et
al
provid
first
vivo
evid
import
role
neutrophil
influx
viralassoci
asthma
exacerb
studi
sinc
demonstr
number
neutrophil
correl
level
rhinoviru
infect
level
nasal
lavag
correl
degre
airway
respons
asthmat
subject
contrast
healthi
subject
level
found
significantli
increas
granulocyt
colonystimul
factor
level
also
increas
nasal
lavag
fluid
sputum
later
circul
rhinoviru
infect
increas
concentr
circulatori
granulocyt
colonystimul
factor
could
turn
act
bone
marrow
increas
circul
neutrophil
count
use
murin
model
human
rhinoviru
infect
nagarkar
et
al
recent
show
receptor
elrposit
cxc
chemokin
requir
rhinovirusinduc
neutrophil
airway
inflamm
neutrophil
tnfa
releas
requir
airway
hyperrespons
product
neutrophil
activ
could
also
caus
airway
obstruct
product
elastas
upregul
goblet
cell
mucu
secret
combin
data
suggest
rhinoviru
infect
airway
epitheli
cell
might
potenti
preexist
inflamm
enhanc
product
neutrophil
chemoattract
neutrophil
airway
inflamm
viral
infect
also
trigger
increas
recruit
activ
eosinophil
airway
eosinophil
granul
protein
detect
nasal
secret
asthmat
children
wheez
ill
caus
rhinoviru
rsv
children
level
potent
chemotact
cytokin
activ
eosinophil
also
significantli
increas
experiment
rhinoviru
infect
bronchial
eosinophil
infiltr
observ
healthi
asthmat
adult
howev
asthmat
subject
eosinophil
infiltr
prolong
still
present
week
infect
adult
allerg
rhiniti
experiment
rhinoviru
infect
increas
allergeninduc
eosinophil
number
bal
fluid
asthmat
adult
eosinophil
product
increas
sputum
addit
airway
hyperrespons
correl
rhinovirusinduc
eosinophil
reflect
increas
eosinophil
cation
protein
sputum
supernat
vitro
experi
indic
rhinovirus
activ
eosinophil
directli
rather
probabl
activ
virusinduc
mediat
adhes
molecul
cytokin
secret
cell
epitheli
cell
airway
cell
remain
unclear
howev
whether
eosinophil
contribut
host
defens
immunopatholog
observ
viral
infect
murin
model
rsv
infect
increas
number
eosinophil
improv
viral
clearanc
reduc
airway
dysfunct
suggest
eosinophil
might
protect
mucociliari
clearanc
critic
innat
defens
system
mucu
overproduct
one
major
symptom
asthma
exacerb
significantli
contribut
morbid
mortal
asthmat
subject
mucu
occlud
lumen
asthma
exacerb
quit
complex
biolog
materi
compris
mixtur
mucin
plasma
protein
product
cell
death
inde
recent
proteom
analysi
identifi
differ
protein
human
induc
sputum
asthmat
subject
major
mucin
compon
airway
mucu
secret
contribut
viscoelast
properti
mucu
et
al
recent
demonstr
rhinoviru
induc
mucin
product
epitheli
cell
depend
viral
replic
least
partli
tolllik
receptor
tlr
prr
specif
recogn
viral
doublestrand
rna
hewson
et
al
recent
shown
rhinoviru
induct
bec
occur
nuclear
factor
nf
kbdepend
induct
matrix
metalloproteinasemedi
tgfa
releas
activ
epiderm
growth
factor
receptordepend
cascad
culmin
specif
protein
transactiv
promot
experiment
infect
hewson
et
al
also
demonstr
increas
product
healthi
asthmat
volunt
vivo
relat
viral
load
asthmat
subject
healthi
volunt
tlr
recogn
respond
varieti
pathogenassoci
molecular
pattern
first
indic
tlr
recogn
viral
pathogenassoci
molecular
pattern
case
rsv
fusion
protein
sinc
sever
studi
demonstr
respons
viral
infect
involv
induct
type
interferon
particularli
relev
relat
rna
virus
recogn
respond
singlestrand
viral
rna
doublestrand
viral
rna
respect
recogn
rhinoviru
upregul
infect
block
suppress
antivir
respons
rhinoviru
replic
releas
increas
roponen
et
al
recent
demonstr
impair
function
adolesc
mildtomoder
asthma
howev
abil
ligand
induc
key
antivir
molecul
similar
asthmat
control
group
moreov
polymorph
shown
associ
asthma
identifi
novel
risk
gene
subject
asthma
relat
disord
asthma
diseas
character
type
tcell
infiltr
product
viral
infect
hand
character
type
tcell
respons
lead
product
ifng
balanc
h
h
cytokin
product
crucial
viral
clearanc
data
support
suggest
within
preexist
type
cytokin
allerg
asthmat
microenviron
normal
effect
type
antivir
immun
respons
might
inhibit
immun
respons
skew
toward
type
respons
gern
et
al
demonstr
sputum
mrna
ratio
infect
invers
relat
peak
cold
symptom
score
time
viral
clearanc
suggest
strong
h
respons
key
limit
viral
replic
recent
studi
involv
experiment
infect
identifi
defici
induct
h
cytokin
augment
induct
h
cytokin
asthmat
subject
addit
h
cytokin
associ
protect
exacerb
wherea
h
cytokin
associ
increas
diseas
sever
observ
support
import
role
rhinovirusinduc
lower
airway
inflamm
precipit
asthma
exacerb
perhap
impair
h
augment
h
respons
epitheli
cell
infect
rhinoviru
secret
promot
tcell
chemotaxi
level
chemokin
bind
increas
virusinduc
asthma
exacerb
inde
distinguish
virusinduc
nonvirusinduc
exacerb
defect
h
respons
also
implic
rsvinduc
bronchiol
children
defici
h
rel
increas
h
immun
respons
rsv
infect
better
viral
clearanc
like
acut
bronchiol
stronger
type
respons
milder
ill
without
bronchiol
addit
studi
demonstr
children
rel
increas
h
cytokin
profil
rsvinduc
bronchiol
increas
risk
wheez
followup
nfkb
transcript
factor
express
numer
cell
type
play
key
role
express
mani
proinflammatori
gene
lead
synthesi
cytokin
adhes
molecul
chemokin
respiratori
mucin
growth
angiogen
factor
increasingli
larg
bodi
evid
demonstr
clear
role
nfkb
subject
stabl
asthma
acut
exacerb
greater
level
nfkb
activ
seen
bronchial
biopsi
specimen
sputum
cell
cultur
bec
stabl
untreat
asthmat
subject
compar
seen
nonasthmat
subject
ppbmc
adult
moder
sever
asthma
well
children
moder
asthma
higher
level
nfkb
protein
express
healthi
subject
viral
infect
caus
upregul
plethora
proinflammatori
molecul
nfkbdepend
manner
includ
neutrophil
chemokin
tcell
chemokin
addit
variou
cytokin
growth
factor
induc
includ
gmcsf
fibroblast
growth
factor
fgf
vascular
endotheli
growth
factor
vegf
adhes
molecul
respiratori
mucin
includ
also
nfkb
depend
although
understand
nfkb
signal
molecul
expand
member
complex
signal
cascad
repres
best
therapeut
target
asthma
exacerb
far
clear
moreov
fundament
consider
benefici
role
nfkb
host
respons
infecti
agent
essenti
interferon
induct
respons
infect
furthermor
question
known
nfkb
inhibitor
corticosteroid
partial
effect
control
exacerb
illustr
greater
level
understand
requir
host
respons
infect
part
genet
program
recent
year
larg
number
genet
polymorph
relev
infect
asthma
identifi
includ
sever
polymorph
prr
tlr
see
earlier
shown
associ
infect
sever
asthma
addit
gene
involv
regul
interferon
product
identifi
transcript
factor
central
import
regul
ifng
product
function
gene
locat
chromosom
h
cytokin
cluster
involv
develop
allerg
diseas
almost
polymorph
locu
analyz
eleven
significantli
associ
atopi
total
ige
level
specif
ige
level
addit
suppressor
cytokin
signal
regul
ifng
signal
antivir
respons
signific
associ
polymorph
promot
adult
asthma
observ
polymorph
result
increas
product
protein
turn
inhibit
phosphoryl
signal
transduc
activ
transcript
respons
ifnb
stimul
addit
gene
involv
innatet
h
respons
infect
associ
risk
asthma
singl
nucleotid
polymorph
h
gene
also
potenti
import
forton
et
al
recent
identifi
haplotyp
within
gene
locu
confer
increas
risk
sever
primari
rsvinduc
bronchiol
earli
infanc
like
technolog
continu
improv
futur
studi
reveal
numer
polymorph
play
key
role
asthmat
immun
respons
viral
infect
central
role
bronchial
epithelium
play
asthma
well
appreci
remain
less
clear
effect
viral
infect
asthmat
airway
chronic
inflammatori
respons
specif
last
effect
might
lead
airway
wall
remodel
worsen
fix
airflow
obstruct
j
allergi
clin
immunol
volum
number
leigh
et
al
recent
demonstr
rhinoviru
infect
cultur
epitheli
cell
led
upregul
amphiregulin
activin
vegf
protein
level
mediat
strongli
implic
remodel
process
amphiregulin
member
epiderm
growth
factor
famili
releas
respons
airway
epitheli
injuri
engag
epiderm
growth
factor
receptor
drive
alter
repair
process
characterist
airway
remodel
activin
member
tgfb
superfamili
implic
subepitheli
fibrosi
characterist
airway
remodel
express
vegf
receptor
increas
asthmat
subject
vegf
major
proangiogen
activ
asthmat
airway
increas
size
number
airway
wall
blood
vessel
characterist
airway
remodel
even
subject
mild
asthma
overexpress
vegf
airway
mice
shown
result
vascular
airway
remodel
moreov
nasal
lavag
sampl
subject
confirm
natur
rhinoviru
infect
show
significantli
higher
vegf
protein
level
peak
cold
symptom
compar
baselin
level
control
level
although
epitheli
cell
main
target
rhinoviru
infect
studi
indic
rhinoviru
might
detect
subepitheli
layer
mean
situ
hybrid
human
lung
fibroblast
suscept
rhinoviru
infect
possibl
rhinoviru
gain
access
underli
fibroblast
epitheli
disrupt
occur
asthmat
airway
suscept
might
allow
rhinoviru
replic
lower
airway
develop
especi
asthmat
subject
reduc
protect
offer
epitheli
deriv
interferon
bedk
et
al
recent
infect
normal
asthmat
airway
fibroblast
vitro
illustr
abil
fibroblast
support
viral
replic
vigor
proinflammatori
respons
induct
latter
respons
compound
exist
airway
inflamm
contribut
exacerb
furthermor
studi
demonstr
exogen
ifnb
protect
fibroblast
infect
provid
support
potenti
use
therapi
virusinduc
asthma
exacerb
tgfb
key
regul
wound
repair
heal
increas
tgfb
tgfb
mrna
level
bal
fluid
endobronchi
biopsi
specimen
respect
report
patient
asthma
thoma
et
al
recent
demonstr
rhinoviru
replic
enhanc
fibroblast
fibroblast
subject
asthma
link
defici
type
interferon
respons
tgfb
might
therefor
act
endogen
immunosuppress
promot
viral
replic
evolut
virusinduc
asthma
exacerb
sever
therapeut
strategi
potenti
alter
natur
histori
virusinduc
asthma
exacerb
includ
prevent
infect
either
vaccin
mab
antivir
agent
viral
attach
inhibitor
viral
proteas
inhibitor
antiinflammatori
treatment
corticosteroid
macrolideketolid
antibiot
supplement
protect
antivir
respons
treatment
interferon
whichev
intervent
consid
treatment
would
need
taken
earli
cours
infect
maxim
chanc
success
easi
administ
safe
present
safe
effect
human
vaccin
rsv
rhinoviru
antigen
divers
serotyp
rhinoviru
mean
creat
truli
success
vaccin
extrem
difficult
task
recent
attent
focus
live
attenu
vaccin
develop
subunit
vaccin
rsv
combin
h
adjuv
although
neither
approach
like
readi
clinic
use
time
palivizumab
mab
rsv
fusion
protein
us
food
drug
administrationapprov
mab
rsv
murin
model
reduc
viral
load
acut
diseas
chronic
lung
function
abnorm
random
control
trial
children
result
reduct
rsvinduc
hospit
recent
prospect
casecontrol
studi
atrisk
preterm
infant
demonstr
protect
recurr
wheez
motavizumab
secondgener
deriv
palivizumab
higher
affin
rsv
fusion
glycoprotein
rat
model
time
greater
antirsv
activ
lower
respiratori
tract
compar
palivizumab
larg
phase
noninferior
studi
compar
motavizumab
palivizumab
rsv
prevent
highrisk
children
motavizumab
demonstr
fewer
rsvinduc
hospit
reduct
incid
rsvspecif
outpati
lower
respiratori
tract
infect
addit
motavizumab
significantli
reduc
viral
load
day
treatment
children
hospit
rsv
suggest
role
rsv
treatment
prevent
motavizumab
current
pend
us
food
drug
administr
approv
although
theoret
possibl
interfer
everi
step
infecti
cycl
respiratori
tract
virus
viral
attach
viral
entri
uncoat
translat
replic
onward
viru
releas
except
neuramidas
inhibitor
influenza
infect
approach
met
success
thu
far
great
major
rhinovirus
use
enter
cell
boehringeringelheim
develop
solubl
receptor
call
tremacamra
show
margin
benefit
symptom
viral
replic
develop
clinic
cold
test
therapi
asthma
exacerb
requir
time
daili
treatment
along
fact
realli
effect
use
within
hour
infect
led
develop
halt
longact
neutral
antibodi
akin
palivizumab
rsv
would
like
promis
approach
pleconaril
antivir
drug
picornaviru
infect
current
studi
subject
asthma
exacerb
block
uncoat
attach
bind
hydrophob
pocket
within
capsid
similar
drug
also
activ
develop
inhibit
essenti
viral
proteas
hrv
investig
antirhinoviru
treatment
earli
work
seem
promis
proteas
requir
replic
cleavag
viral
polyprotein
ruprintrivir
intranas
administ
proteas
inhibitor
good
antivir
activ
rhinoviru
serotyp
unfortun
despit
encourag
result
experiment
infect
studi
natur
infect
studi
signific
effect
viral
load
symptom
clinic
develop
halt
sever
inhibitor
proteas
none
test
clinic
trial
thu
far
inhal
corticosteroid
longact
bagonist
combin
therapi
glucocorticosteroid
far
wide
use
drug
subject
moder
sever
asthma
potent
antiinflammatori
activ
despit
patient
asthma
continu
exacerb
recent
year
everincreas
bodi
work
support
use
combin
longact
bagonist
salmeterol
formoterol
highlight
superior
combin
therapi
either
drug
isol
although
studi
whole
fail
identifi
trigger
asthma
exacerb
like
major
secondari
viral
infect
edward
et
al
demonstr
combin
salmeterol
fluticason
treatment
synergist
suppress
induct
neutrophil
chemoattract
activ
lymphocyt
chemokin
activ
tcell
chemokin
rhinoviru
infect
vitro
skevaki
et
al
recent
demonstr
corticosteroid
budesonid
effect
suppress
rhinovirusmedi
induct
proinflammatori
remodelingassoci
fgf
vegf
mediat
bec
concentrationdepend
manner
formoterol
treatment
alon
also
suppress
product
fgf
bronchial
epithelium
howev
combin
budesonid
formoterol
demonstr
concentrationdepend
addit
synergist
effect
suppress
rhinovirusinduc
vegf
volonaki
et
al
demonstr
fluticason
salmeterol
administ
individu
abl
reduc
rhinovirusinduc
vegf
product
addit
factor
howev
inhibit
vegf
synergist
moreov
product
inhibit
either
fluticason
salmeterol
alon
significantli
reduc
substanc
present
effect
suppress
growth
factor
highlight
certainli
repres
plausibl
mechan
drug
might
inhibit
remodel
inflammatori
process
increas
bodi
work
highlight
immunemodulatori
effect
macrolid
antibiot
distinct
antimicrobi
action
jang
et
al
demonstr
reduc
express
treatment
erythromycin
rhinovirusinfect
epitheli
cell
gielen
et
al
recent
shown
pretreat
bec
azithromycin
significantli
increas
interferon
interferonstimul
gene
mrna
protein
express
addit
azithromycin
reduc
rhinoviru
replic
releas
infant
rsvinduc
bronchiol
clarithromycin
reduc
system
inflamm
acut
led
fewer
wheez
episod
follow
month
although
small
studi
much
larger
studi
asthmat
adult
random
receiv
either
telithromycin
ketolid
antibiot
placebo
result
greater
reduct
asthma
symptom
score
lung
function
ketolid
group
safeti
concern
limit
widespread
use
ketolid
studi
need
clarifi
posit
macrolid
manag
asthma
exacerb
wark
et
al
observ
defici
ifnb
respons
bec
asthmat
subject
rhinoviru
infect
phase
trial
involv
inhal
ifnb
onset
respiratori
tract
viral
infect
asthmat
subject
current
underway
treatment
corticosteroidresist
asthmat
subject
ifna
one
case
seri
led
improv
lung
function
reduct
oral
corticosteroid
use
howev
major
subject
experienc
side
effect
includ
flulik
ill
nausea
headach
number
trial
assess
use
intranas
administ
healthi
volunt
undergo
experiment
rhinoviru
infect
studi
show
dosedepend
improv
symptom
score
reduc
viral
shed
side
effect
problem
approach
use
interferon
aim
boost
host
defens
rather
target
specif
respiratori
virus
signific
advantag
specif
antivir
approach
would
treat
virusinduc
asthma
attack
rather
caus
specif
viru
despit
problem
side
effect
earli
trial
suffici
vitro
vivo
data
support
reexamin
treatment
approach
similar
approach
aim
boost
antivir
activ
tlr
ligand
also
develop
respiratori
tract
viral
infect
play
key
role
pathogenesi
asthma
exacerb
despit
specif
treatment
exist
abl
significantli
alter
clinic
outcom
infect
numer
therapeut
strategi
consid
howev
success
hamper
problem
viru
specif
side
effect
deliveri
problem
need
earli
administr
diagnosi
infect
result
ongo
clinic
trial
ifnb
mani
problem
address
await
interest
indepth
studi
molecular
pathway
underli
virusinduc
inflamm
also
requir
identifi
new
target
develop
novel
therapi
use
gene
array
analysi
determin
whether
asthma
associ
uniqu
pattern
epitheli
cell
gene
express
viral
infect
potenti
radic
improv
understand
immun
pathway
involv
potenti
identifi
new
therapeut
target
although
approach
perform
vitro
cultur
epitheli
cell
gene
express
either
bec
alveolar
macrophag
experiment
infect
vivo
yet
perform
moreov
futur
studi
need
sampl
asthmat
children
nonatop
asthmat
subject
gain
complet
pictur
role
virus
asthma
exacerb
final
understand
effect
virusinduc
exacerb
subsequ
remodel
develop
sever
airflow
obstruct
requir
studi
